| INTRODUCTION
The peripheral nervous system may be involved in the course of lymphoproliferative diseases as direct spread of disease to the nerves (neurolymphomatosis) or secondary to infectious, metabolic or paraneoplastic processes. In addition, iatrogenic neuropathies and, in the advanced stages, entrapment mononeuropathies secondary to cachexia or neuropathies due to nutritional deficiency may also occur.
The neuropathies in lymphomas may present with heterogeneous clinical features depending on the topography (sensory ganglia, roots, peripheral nerves, and plexi) and the involved structures (myelin, axon, and cell body). Peripheral neuropathy may sometimes be the symptom at onset of the disease, preceding the diagnosis of lymphoma. Medical history and clinical features (focal vs diffuse involvement, symmetric/asymmetric pattern), presence of pain, or other associated manifestations as well as the temporal evolution are all features to be considered in guiding the diagnosis ( Table 1) .
The following is a review on the most common peripheral neurological complications of lymphomas, providing clinical and instrumental clues that may help in the diagnostic workup.
| LYMPHOMA CLASSIFICATION
Malignant lymphomas are a heterogeneous group of hematological neoplasms that arise from lymphocytes at different maturation stages.
They represent the fifth to seventh most frequent cancer in the Western World (International Agency for Research on Cancer, IARC data).
The classification of malignant lymphomas has always been an everchanging task, as the advancements in understanding the genetic and molecular determinants of the different lymphoma subtypes periodically lead to revisions of the classification and introduction of new provisional entities. The last lymphoma classification has recently been updated in 2016 by a panel of hematopathologist experts on behalf of the World Health Organization (WHO). 1 In this last proposal, significant progresses have been made in the description of both B
and T-cell-derived neoplasms.
Lymphomas may arise in any organ and at any age. There is a slight male predominance and the incidence increases with age. The highest incidence occurs in industrialized countries, including United
States, Canada, Australia, Europe, and Japan, and the lowest incidence has recently been approved for the treatment of relapsed/refractory HL. It has been reported that the checkpoint inhibitors, by virtue of their ability to reactivate T-lymphocytes, can trigger an immunemediated damage to both the central and the peripheral nervous system also with disabling symptoms. 5, 6 Radiation-induced plexopathy may also be a delayed iatrogenic complication of HL (see paragraph on plexopathies), although increasingly less common due to current smaller fields of irradiation. In HL, neuropathies due to paraneoplastic mechanisms or to lymphoma dissemination to the peripheral nervous system have rarely been reported (see specific paragraphs).
In the case series by Reference, 7 HL was associated only with predominantly sensory or motor demyelinating neuropathies. A previously reported increased incidence of acute polyradiculoneuritis (Guillain-Barrè syndrome, GBS) in HL 8, 9 has not been confirmed on more recent larger scale studies. people/year and a median age at diagnosis of 72 years. It is Recently, both ibrutinib and bortezomib have been introduced in the armamentarium of relapsed WM, proving activity and long-term disease control in the majority of patients, including some patients with anti-MAG antibody neuropathy. 32 Obinutuzumab has also been reported as possible therapeutic option in anti-MAG neuropathy. 19 Cryoglobulins-associated neuropathy also benefit from rituximab, as well as from steroids and plasma-exchange in case of lifethreatening manifestations. 26 IgM AL neuropathy may respond to bortezomib-or bendamustine-based chemotherapy and may be ibrutinib. 33 
| HIGH-GRADE NHL
DLBCL is the most common type of NHL among adults, with an annual incidence of seven to eight cases per 100 000 per year in the DLBCL may be associated with all types of peripheral neuropathies, including mono-or multi-neuropathy or vasculitis. 36 Primary infiltration of peripheral nervous system in DLBCL has also been reported, more commonly with infiltrative mononeuropathies, especially sciatic nerve involvement, but also with multifocal localization 36 .
37,38
Aggressive B-cell lymphomas may also present with acute and painful radiculopathy. 7 46 Peripheral nervous system manifestations have been described with a wide spectrum of clinical pictures from acute polyradiculoneuropathy 47 to multiple mononeuropathy 48 .
| CASTLEMAN'S DISEASE
The prognosis of the intravascular lymphoma is usually dismal, but has been improved by immunochemotherapy, in particular with rituximab. However, a significant proportion of patients relapse, especially those with central nervous system manifestations. 45 
| PARANEOPLASTIC NEUROPATHIES
Paraneoplastic neurological syndromes are rare neurological disorders occurring in less than 1% of people with malignancy not due to direct tumor infiltration or metastases, infection, ischemia, metabolic or nutritional deficits, or chemotherapy side effects. 49 Paraneoplastic neurological syndromes in lymphomas are mostly related to central nervous system manifestation (limbic encephalitis and cerebellar degeneration), whereas peripheral paraneoplastic manifestations are extremely rare. In the European Paraneoplastic neurological syndromes database (the largest cohort of patients with paraneoplastic neurological syndromes so far described), of the 899 patients with an associated tumor only 6.4% had lymphomas. 50 Subacute sensory neuronopathy is the most frequent peripheral paraneoplastic neurological syndromes, 50 but it rarely occurs in lymphomas. 10, 51 The frequency and characteristics of the peripheral paraneoplastic neurological syndromes in lymphoma from a study on 974 patients of the Paraneoplastic neurological syndromes-EURONET database revealed that 4/24 patients with HL and 16/29 patients with NHL had peripheral nervous system involvement, the most common being acute (two cases) or chronic (seven cases) demyelinating polyradiculoneuropathy, the latter antedating the diagnosis of NHL in six of seven patients.
Five patients with NHL had a sensory-motor neuropathy and two patients a sensory-motor neuronopathy. Motor neuronopathy has also been described as part of paraneoplastic neurological syndromes in lymphoma. 10, 52, 53 Notably, onconeural antibodies are lacking in paraneoplastic neuropathies in lymphomas, 10, 51 making it more difficult to define the paraneoplastic nature of the disease. Considering that in patients with lymphoma other causes of neuropathy may be present, among which chemotherapy-induced neuropathy, amyloid deposition, root or nerve infiltration, or infection, an accurate differential diagnosis is mandatory. Apart from some patients whose neuropathy improves after lymphoma treatment, the paraneoplastic nature is difficult to be ascertained. Moreover, it is likely that the immune dysregulation associated with the lymphoproliferative disorders may predispose to the occurrence of demyelinating immunemediated neuropathies, such as CIDP, rather than being the neuropathies of paraneoplastic nature. 11 Consistently, the low prevalence in the paraneoplastic neurological syndromes-EURONET database of GBS in lymphoma patients, which differs from the literature data, 8, 9 may be ascribed to the fact that this rare occurrence is often considered coincidental.
| NEUROLYMPHOMATOSIS
Neurolymphomatosis is the histologically documented infiltration of the peripheral nervous system from lymphomas. In the IPCG study, 84% cases were positive to PET-CT scan.
61,71
Limitations of 18-FDG PET-CT include lack of specificity because infection or inflammation can also produce a positive result. Further limitations of PET are that some lymphomas are 18-FDG PET negative and that only seldom does anything actually light up in the nerves themselves because of the low levels of invasion.
Ultrasound has been described as useful non-invasive, highly sensitive but with low-specificity tool for identifying peripheral nerve involvement in B-cell lymphoma. 72 Nerve infiltration and malignant neovascularization might be detected as focal nerve enlargement and increased vascularization in Doppler sonography, thus helping identify a favorable site for nerve biopsy. CSF studies show elevated protein, low glucose, and elevated cell counts in most subjects. 61, 74 However, in the IPCG study, malignant cells and suspicious cytology were reported only in 40% and 13% of cases, respectively. 61 However, the lymphoma cells must always be searched for in CSF with flow cytometry.
The prognosis of neurolymphomatosis is poor, also due to the common late diagnosis. However, when early diagnosis and proper treatment are achieved, in almost half of the patients a complete hematological response is gained. Neurological deficits rarely recover completely, although sometimes they do. 77 Corticosteroids should be avoided before the diagnosis of neurolymphomatosis, as the lymphotoxic effects of steroids may cause false negative histology and PET-CT scan. Moreover, the clinical benefit of corticosteroids monotherapy is short. 60 Once the diagnosis is achieved, patients undergo systemic chemotherapy alone or combined with intrathecal chemotherapy or external radiotherapy. 60, 61 In the absence of systemic lymphoma, it is unclear whether poly-chemotherapy (ie, CHOP, prednisone, methotrexate, doxorubicin, cyclophosphamide, and etoposide (ProMACE), and hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (HyperCVAD)) confers any survival benefit compared to single-agent chemotherapy such as high-dose methotrexate. 60 Radiotherapy can be used with curative intent but also for palliation. However, it remains unclear whether radiotherapy adds any benefit to chemo-sensitive tumor. In the IPCG study, treatment was administrated in 90% of patients: 70% systemic chemotherapy, 49% intrathecal chemotherapy, and 34% radiotherapy. Both intravenous and intrathecal treatment were administrated to 40% of subjects, 8.5% received only intrathecal therapy, and 10% received radiotherapy alone. 61 Target therapies such as monoclonal antibodies and kinase inhibitors have rarely been used in neurolymphomatosis. In our report single-agent rituximab, an anti-CD20 antibody was active and effective in CLL-mediated neurolymphomatosis. 15 Another case of neurolymphomatosis has been treated with long-term rituximab with eventual complete recovery (from being wheel-chair bound to independent walking 77 ( Figure 3 ). In the IPCG study, four patients received rituximab in combination with CHOP. 61 Overall response rate is obtained in less than 50% of patients and another quarter of patients stabilized the diseases. The median overall survival is usually less than 1 year but is markedly shorted in unresponsive and relapsed patients. 61 Only few chemotherapeutic drugs are able to pass the blood brain barrier, but among them high-dose methotrexate, cytarabine, procarbazine, thiothepa, and rituximab showed the most encouraging results. Ferreri et al. 78 recently proved that MATRIx protocol (methotrexate, cytarabine, thiothepa, and rituximab) was able to induce a higher rate of complete remission, longer progression free survival, and improved overall survival as compared to standard highdose methotrexate-cytarabine in primary central nervous system lymphoma. However, its efficacy in patients with neurolymphomatosis is unknown.
| PLEXOPATHIES
Plexopathies in lymphomas are usually iatrogenic, as delayed side effect of radiotherapy, especially in HL requiring "mantle field" radiation therapy. 79, 80 Iatrogenic plexopathies generally occur years after radiation therapy, are painless and slowly progressive. A common clinical picture is the dropped head syndrome, characterized by severe paravertebral extensor muscle weakness, resulting in chin-on-chest deformity. 79, 81 However, radiotherapy-induced plexopathies is nowadays rarer due to contemporary smaller fields of irradiation for HL. Acute plexopathy in the early phase of radiation therapy is also described, and they are often associated with pain. Rarely acute brachial plexopathy may be the manifestation of lymphoma infiltration 82 or of neurolymphomatosis 83 . 84 Plexopathy in previously radiationtreated lymphomas requires a thorough diagnostic assessment aiming at distinguishing tumor recurrence from post-radiation myelopathy, which might exhibit the same clinical picture, although the first is generally more painful. Whereas solid tumor recurrence in plexi is often associated with Horner's syndrome, 85 this has rarely been described in lymphomas, generally secondary to bulky lymphadenopathy. 86 Recently, the availability of Magnetic resonance neurography (multiplanar T2-based sequences with fat suppression) has allowed a better evaluation of specific nerve morphological features (such as caliber, internal fascicular pattern and the amount of perineurial-endoneurial fluid), thus implementing the conventional MRI where injured plexus showed hypertense and enhanced signal. Additional radiological hints of post-radiation plexopathy may be found in the surrounding tissues. 87, 88 The implementation of magnetic resonance neurography with diffusion-weighted sequences appears promising in the investigation of cancer patient. 65, 89 In addition, 18-FDG PET may have a supplemental role in ruling out malignancy. 90 Also, nerve ultrasound may provide useful information in the evaluation of post-radiation plexopathy revealing reduced cross-sectional area of the irradiated plexus. 91 
| SPINAL NERVE ROOTS
Spinal roots may often be involved in patients with lymphomas, mainly by viral infections, the most common being VZV infection, triggered by the immune dysregulation linked to the disease itself 92 or favored by the therapy. 93, 94 VZV in NHL with severe motor involvement has also been described. 95 The nerve roots may be affected due to leptomeningeal spread of lymphoma itself, generally NHL. [96] [97] [98] Radicular pain (in one or more segments) is almost always present, and often asymmetric, and may be associated with spinal cord symptoms secondary to spine compression. Aggressive B-cell lymphomas present more commonly with acute and painful radiculopathy. Grisold et al. 101 proposed the meninges as crucial barrier between meningoradicular spread and neurolymphomtosis. Specifically, when the neoplastic spread is restricted to the CSF and meningeal involvement is likely, CSF analysis is able to provide useful information. Conversely, when the lymphomatous involvement is limited to the peripheral nerves, CSF may be negative. 96 The identification of the two different patterns, through neurophysiology, neuroimaging, CSF, and histological analysis may be crucial for choosing the appropriate therapy. 101 (Table 2) .
| CHEMOTHERAPY-INDUCED NEUROTOXICITY
Vinka alkaloids (vincristine, vinblastine, vinorelbine, and vindesine) that act by binding to tubulin and blocking microtubule formation with consequent cell apoptosis are used to treat acute lymphoblastic leukemias as well as HL and NHL. Vincristine is one of the most commonly used drugs in chemotherapy protocols, also in children, and can cause a length-dependent axonal sensory-motor peripheral neuropathy, often resulting in dose limitation. Sensory involvement (paresthesias and sensory loss) is commonly the first sign, followed by motor weakness. Small fibers may be affected as well, with neuropathic pain and autonomic symptoms, including severe constipation. Vincristineinduced cranial neuropathies have also been reported. The neuropathy is usually severe but reversible within months after therapy discontinuation, even if it can present or worsen after therapy withdrawal (coasting effect). 104, 105 A progressive increase in the risk of developing vincristine peripheral neuropathy seems to be associated with older age and higher cumulative dose. 104 In pediatric population, motor involvement seems to be predominant, with possible asymmetric features, while cranial neuropathies are rare. Severe GBSs with rapid onset have also been described, mostly during the chemotherapy-induction phase. The concomitant administration of anti-fungine prophylactic medications has also been reported to be associated with a higher risk of developing peripheral neuropathy, likely for interference with cytochrome P450 drug metabolism.
Polymorphisms in cytochrome P450 CYP3A5 seem to be modifiers in the incidence and severity of vincristine-induced peripheral neurotoxicity. [106] [107] [108] Finally, vincristine administration may trigger severe neuropathies in patients with a previous (often unknown)
hereditary neuropathy of Charcot-Marie-Tooth (CMT) type. [109] [110] [111] [112] Bortezomib and carfilzomib are proteasome inhibitors proven to be effective in the treatment of multiple myeloma, WM and mantle cell lymphoma. Bortezomib most common adverse effect is an axonal sensory-motor peripheral neuropathy, often presenting with prominent sensory impairment and severe neuropathic pain. neurotoxic dose threshold rather than a traditional cumulative dose effect might be involved. 114, 115 Moreover, cumulative doses ≥45 mg/m 2 have been associated with risk of neurotoxicity increasing up to 50%, 116 despite the significant reduction of its incidence after the introduction of subcutaneous administration. 117, 118 Although less common, another pattern characterized by demyelinating features and a predominant motor involvement has been described. Signs and symptoms are usually reversible upon dose adjustment or therapy discontinuation. An increased susceptibility to compression neuropathies has also been reported. Carfilzomib, a second-generation proteasome inhibitor approved for multiple myeloma treatment, shares similar adverse effects with bortezomib, but has been reported to be less neurotoxic. 119 Lenalidomide, a thalidomide analogue with immune-modulating and anti-angiogenetic activities, shows a better safety profile when compared with its precursor, especially regarding neurotoxicity. 120 Lenalidomide has also been successfully used in patients with POEMS syndrome. Peripheral neurotoxicity has also been described for newer drugs such as the immune checkpoint inhibitors (ie, nivolumab and pembrolizumab), recently approved for relapsed/refractory HL. These monoclonal antibodies target programmed cell death protein 1 (PD-1), a cell surface receptor with an important modulatory role on the immune system. The real incidence of peripheral neuropathy as adverse effect is unknown but patients with cranial, optic, and diffuse peripheral neuropathies have been reported. Moreover, subacute polyradiculoneuropathy has also been observed. 125 Being relatively new drugs, specific data regarding the clinical features and the timing of onset and recovery of the neuropathy are still lacking. 105, 117 Nelarabine, a purine nucleoside analogue used in lymphoblastic Tcell lymphoma, can cause severe neurotoxicity, mostly presenting with acute polyradiculoneuritis. This side effect is more likely occurring upon intrathecal administration. 126, 127 Finally, peripheral nervous system involvement in course of chronic graft-versus-host disease (cGvHD), a major side effect of allogeneic hematopoietic stem cell transplantation, a procedure most often applied in heavily pre-treated relapsed lymphoma patients, should be mentioned. It may present with different clinical manifestations, among which cramps, large and small fibers polyneuropathy of different degree of severity and impact on the quality of life. [128] [129] [130] A recent prospective study on 27 patients with cGvHD 131 reported that almost all (92.6%) the patients developed peripheral neuropathy, 6%
with mixed large and small fibers neuropathies, the latter associated with pain.
| CRANIAL NERVES INVOLVEMENT IN LYMPHOMA
The cranial nerves involvement is rare in the course of lymphomas, and it is seen in only 5% of patients with DLBCL. 132 It might be both the initial presentation of a lymphoma and the site of relapse. Despite rare, cranial nerves involvement is more frequent in hematological than in solid tumors, and lymphoma should always been considered in the presence of unexplained cranial nerves damage.
Cranial nerves involvement may be secondary to direct nerves infiltration (neurolymphomatosis), leptomeningeal ( Figure 4A ) or hematogenous spread or, more rarely, may be due to lymphoma associated vasculitis and paraneoplastic syndrome. Interestingly, also anastomoses between nerves can favor tumor spread from one nerve to another (eg, V and VII cranial nerves). 96 Notably, spreading of lymphoma along cranial nerves might occur through cranial nerves foramina which may represent a path for disease diffusion. In the differential diagnosis, infectious comorbidities (eg, VZV) and side effects of therapies (chemotherapy and radiation) should be considered. 8, 133 Clinical presentation may be a mononeuropathy or a multineuropathy, 132, 134 with symptoms consistent with the cranial nerve involved (eg, ptosis, facial palsy, facial hypoesthesia or paresthesia, dysphagia, and visual impairment). Pain may also be present. In case of meningeal spreading headache, vomit and symptoms of intracranial hypertension may contribute to the clinical spectrum. 134, 135 Although rare, optic nerve lymphoma is the most frequent among the cranial nerves lymphomas. Decreased visual acuity, redness and pain of the eye, eyelid edema, conjunctival congestion, and axial proptosis are the most common symptoms. The nerve may be primarily or secondarily involved and, in the latter case, spreading may derive from the central nervous system or from the eye. 136 Moreover, in patients with NHL, other mechanisms might be advocated such as compressive optic neuropathy by orbital lymphoma, paraneoplastic optic neuritis, and central retinal artery occlusion secondary to hyperviscosity. Optic neuropathy may also develop secondary to radiation-related necrosis, vincristine toxicity, or infection. B-cell lymphoma may also be responsible for orbital apex syndrome, consisting in visual impairment from optic nerve dysfunction combined with extraocular muscle palsy.
137
Lymphoma may also primarily locate in the intraocular structures, in oculomotor muscles, or in ciliary nerves.
138-140
Only a few cases of primary trigeminal nerve lymphoma have been reported. 141 Symptoms (ie, trigeminal neuralgia, facial hyperesthesia, and diplopia) are caused by trigeminal dysfunction and cavernous sinus syndrome sometimes misdiagnosed with schwannoma or meningioma. Figure 4B shows a Burkitt lymphoma of trigeminal nerve (mandibular branch) in a patient with trigeminal neuralgia as the clinical onset of the lymphoma (foramen ovale involvement from an extra-assial mass that histology showed to be a Burkitt lymphoma).
Unilateral or bilateral facial nerve palsy has been reported as rare complication of DLBCL or WM. 142, 143 Vagus nerve involvement has been anecdotally reported in a patient with vocal cord paralysis due to DLBCL.
132
Lymphomas may also present with multiple cranial nerve palsies, whose underlying mechanisms consist in malignancy spreading within contiguous nerves or meningeal lymphomatosis. 144 Multiple cranial nerves palsies have also been reported in primary skull base lymphoma, which poses differential diagnosis with other pathological processes involving the skull base, such as meningioma, schwannoma, nasopharyngeal carcinoma, sarcoidosis, granulomatosis with polyangiitis, and carcinomatosis meningitis. 145 Remarkably, when facing with multiple cranial nerves impairment, lymphoma should always be Biopsy is the gold standard for the diagnosis, even if the site of nerve involvement might be arduous to be sampled. 
